Drugs / VUEWAY
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Vueway | — | 2023-12-07 | europa.eu ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07415018 | Jun 2026 → Jul 2027 expected | neoplastic meningitis | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VUEWAY | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07415018 ↗ |
| Route | Intravenous | “Given by IV” NCT07415018 ↗ |